Published February 1, 2025
| Version v2
Publication
Open
A guide to selecting high-performing antibodies for CDK5 (Q00535) for use in western blot, immunoprecipitation, and immunofluorescence
Authors/Creators
-
1.
Montreal Neurological Institute and Hospital
Description
Here we have characterized thirteen CDK5 commercial antibodies for western blot, immunoprecipitation, and immunofluorescence using a standardized experimental protocol based on comparing read-outs in knockout cell lines and isogenic parental controls. This project was supported by Structural Genomics Consortium, a registered charity (no. 1097737). The Structural Genomics Consortium receives funding from Bayer AG, Boehringer Ingelheim, Bristol-Myers Squibb, Genentech, Genome Canada through Ontario Genomics Institute (grant no. OGI196), the EU and EFPIA through the Innovative Medicines Initiative 2 Joint Undertaking (EUbOPEN grant
no. 875510), Janssen, Merck KGaA (also known as EMD in Canada and the United States), Pfizer and Takeda.